Trial Profile

Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metreleptin (Primary)
Indications Congenital generalised lipodystrophy
Focus Pharmacodynamics

Most Recent Events

23 Apr 2021 Primary endpoint has been met. (Total Body Insulin Sensitivity in initiation and Withdrawal cohort), as per Results published in the Journal of Clinical Endocrinology and Metabolism
23 Apr 2021 Primary endpoint has been met. (total energy expenditure in Withdrawal cohort), as per Results published in the Journal of Clinical Endocrinology and Metabolism
23 Apr 2021 Primary endpoint has been met. (total energy expenditure in initiation cohort), as per Results published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com